Literature DB >> 23345357

Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy.

Anna Gallotti1, Rocio Perez Johnston, Pietro A Bonaffini, Thun Ingkakul, Vikram Deshpande, Carlos Fernández-del Castillo, Dushyant V Sahani.   

Abstract

OBJECTIVE: The objective of our study was to evaluate the MDCT features of incidentally detected neuroendocrine tumors (NETs) of the pancreas, identify features that can predict tumor biology or aggressiveness and long-term outcome, and determine the incidence of "nonbenign" behavior.
MATERIALS AND METHODS: In this retrospective study, 60 histologically verified pancreatic NETs incidentally detected with contrast-enhanced MDCT were included. Various MDCT features such as size, morphology, enhancement, and presence of calcifications were evaluated and were correlated with tumor biology on histopathology. The sensitivity, specificity, predictive values, and accuracy were calculated for MDCT features in predicting nonbenign biology and risk of recurrence.
RESULTS: A total of 32 of 60 (53%) NETs were nonbenign: most were large (mean, 29.1 mm) with a solid or complex pattern. NET size of 3 cm or larger yielded a positive predictive value of 61% for nonbenign tumors and 100% when calcification was present. In 12 patients with recurrence, 92% of NETs were nonbenign. The presence of calcification, local invasion, main pancreatic duct dilatation, vascular invasion, and lymph node enlargement along with angioinvasion and a Ki-67 index greater than 2% on histology were associated with a nonbenign diagnosis and a higher risk of recurrence.
CONCLUSION: Approximately 50% of incidental NETs show uncertain or malignant behavior. Solid tumors 3 cm or larger are commonly nonbenign; however, about 30% of tumors smaller than that size cutoff can be malignant. Nonbenign tumors and those with invasive features on MDCT have a higher incidence of recurrence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23345357     DOI: 10.2214/AJR.11.8037

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  18 in total

1.  Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome.

Authors:  Marco Dioguardi Burgio; Jérome Cros; Nicola Panvini; Thomas Depoilly; Anne Couvelard; Philippe Ruszniewski; Louis de Mestier; Olivia Hentic; Alain Sauvanet; Safi Dokmak; Alex Faccinetto; Maxime Ronot; Valérie Vilgrain
Journal:  Eur Radiol       Date:  2021-05-11       Impact factor: 5.315

Review 2.  Calcified liver metastases from a non-functioning pancreatic neuroendocrine tumor.

Authors:  Terufumi Kawamoto; Tsunekazu Hishima; Kiminori Kimura
Journal:  Clin J Gastroenterol       Date:  2014-08-29

3.  Pancreatic neuroendocrine neoplasms: Correlation between MR features and pathological tumor grades.

Authors:  Feng Jin; Kai Wang; Ting-Ting Qin; Xin Li; Feng Guo; Gui-Na Ma; Xue-Han Hu; Ping Han
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

4.  Pancreatic neuroendocrine tumours: correlation between MSCT features and pathological classification.

Authors:  Yanji Luo; Zhi Dong; Jie Chen; Tao Chan; Yuan Lin; Minhu Chen; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2014-07-22       Impact factor: 5.315

Review 5.  AACE/ACE disease state clinical review: pancreatic neuroendocrine incidentalomas.

Authors:  Miguel F Herrera; Göran Åkerström; Peter Angelos; Clive S Grant; Ana O Hoff; Juan Pablo Pantoja; Rocio Pérez-Johnston; Dushyant V Sahani; Richard J Wong; Gregory Randolph
Journal:  Endocr Pract       Date:  2015-05       Impact factor: 3.443

6.  Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms?

Authors:  Hui Zhu; Lang Ying; Wei Tang; Xiujiang Yang; Bo Sun
Journal:  Radiol Med       Date:  2017-02-07       Impact factor: 3.469

Review 7.  Neuroendocrine tumours: the role of imaging for diagnosis and therapy.

Authors:  Martijn van Essen; Anders Sundin; Eric P Krenning; Dik J Kwekkeboom
Journal:  Nat Rev Endocrinol       Date:  2013-12-10       Impact factor: 43.330

8.  Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients.

Authors:  Dong Wook Kim; Hyoung Jung Kim; Kyung Won Kim; Jae Ho Byun; So Yeon Kim; Ki Byung Song; Nikhil H Ramaiya; Sree Harsha Tirumani; Seung-Mo Hong
Journal:  Eur Radiol       Date:  2015-08-08       Impact factor: 5.315

Review 9.  Workup of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Joseph S Dillon
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

Review 10.  [Neuroendocrine tumors of the abdomen].

Authors:  M Juchems
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.